These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36370634)

  • 21. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
    Weinshenker BG; Wingerchuk DM; Green AJ; Bennett JL; Kim HJ; Pittock SJ; Fujihara K; Paul F; Cutter G; Marignier R; Aktas O; Hartung HP; She D; Smith M; Rees W; Patterson K; Cimbora D; Katz E; Cree BA
    Mult Scler; 2023 Jul; 29(8):945-955. PubMed ID: 37282545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
    Kim HJ; Aktas O; Patterson KR; Korff S; Kunchok A; Bennett JL; Weinshenker BG; Paul F; Hartung HP; Cimbora D; Smith MA; Mittereder N; Rees WA; She D; Cree BAC
    Ann Clin Transl Neurol; 2023 Dec; 10(12):2413-2420. PubMed ID: 37804003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
    Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case report: Transition from anti-CD20 therapy to inebilizumab for 14 cases of neuromyelitis optica spectrum disorder.
    Osborne B; Romanow G; Hemphill JM; Zarif M; DeAngelis T; Kaplan T; Oh U; Pinkhasov J; Patterson K; Levy M
    Front Neurol; 2024; 15():1352779. PubMed ID: 38689876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
    Yan L; Kimko H; Wang B; Cimbora D; Katz E; Rees WA
    Clin Pharmacokinet; 2022 Mar; 61(3):387-400. PubMed ID: 34718986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.
    Pittock SJ; Zekeridou A; Weinshenker BG
    Nat Rev Neurol; 2021 Dec; 17(12):759-773. PubMed ID: 34711906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report.
    Lehrieder D; Zapantis N; Pham M; Schuhmann MK; Haarmann A
    Front Neurol; 2023; 14():1297341. PubMed ID: 38073644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model.
    Lazzaro C; Mazzanti NA; Rossi S; Parazzini F
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.
    Mealy MA; Levy M
    Medicine (Baltimore); 2019 Jun; 98(25):e15944. PubMed ID: 31232925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders.
    Stathopoulos P; Dalakas MC
    Expert Rev Clin Immunol; 2022 Sep; 18(9):933-945. PubMed ID: 35899480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Masuda H; Mori M; Hirano S; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):32-40. PubMed ID: 34362853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.